Reviewer’s report

Title: Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: Implication for vaccine campaign

Version: 2 Date: 12 November 2012

Reviewer: Susanne Hartwig

Reviewer’s report:

Major Compulsory Revisions
1. General comment: statistics
   - please add confidence intervals for all prevalence values and
   - p-values for comparison of round 1 and round 2
   - please explain the choice of 22% of precision for sample size calculation
2. General comment: results
   - presentation of prevalence data not always clear and description of the results in the result section does not always correspond to what is presented in the figures (with vs. without co-infections; only HPV positive samples vs. all samples). Please clarify and specify in the legends of the figures.

Minor Essential Revisions
1. Background/paragraph 4:
   - "As reported elsewhere…" insert reference
2. Methods
   - add used HPV test

Discretionary Revisions
1. General comment: HPV infection is a necessary cause for cervical cancer. However, the distribution of high risk types is different in cancer and in infection due to a different carcinogenic potential of individual high risk types (Guan et al, IJC, 2012). Therefore the distribution of HR types in women with normal cytology can not be considered as a proxy for the distribution in cervical cancer. This should at least be mentioned in the discussion section.
2. General comment: might be interesting to show prevalence data of all or at least the most frequent HPV types
3. Background/paragraph 3:
   - last sentence: as you are referring to quadrivalent vaccine in this paragraph, you should add distribution of LR types 6 and 11
   - mention also bivalent vaccine
**Level of interest:** An article of importance in its field

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** Yes, and I have assessed the statistics in my report.

**Declaration of competing interests:**
I am an employee of Sanofi Pasteur MSD, which markets the quadrivalent HPV vaccine.